Abacus Bioscience

Executive Summary

Abacus Bioscience is a San Diego-based private biotechnology company founded in 2016, focused on developing first-in-class active immunotherapies to overcome immune tolerance for cancer and chronic infections. The company's platform leverages novel biologic and antibody-based therapeutics designed to elicit a robust immune response against disease antigens. By targeting mechanisms of immune suppression, Abacus aims to unlock the potential of the patient's own immune system to fight malignancies and persistent viral infections. While the company is still in early stages of development, its approach addresses significant unmet medical needs, particularly in indications where conventional immune checkpoint inhibitors have limited efficacy. As a private entity with no disclosed funding or valuation, Abacus Bioscience operates with limited public visibility. Its lead programs are not yet in clinical trials, and the company has not reported any pivotal data. The success of Abacus depends on advancing its preclinical candidates into human studies and securing additional capital. The field of active immunotherapy remains competitive, with established players in cancer vaccine and T-cell engager spaces. However, Abacus's focus on overcoming immune tolerance could differentiate its platform. The company's near-term value is contingent upon scientific milestones, such as IND filing or initial proof-of-concept data, that validate its technology.

Upcoming Catalysts (preview)

• 2027Lead program IND filing or Phase I initiation40% success
• TBDNew partnership or licensing deal for platform technology30% success
• 2026Preclinical data presentation at major conference50% success